VRAX

+ Watchlist + Portfolio

Virax Biolabs Group Limited

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.18
52-Week Range: $2.50 – $21.75
Market Cap: $2.75M
P/E (TTM): —
EPS (TTM): -12.64
Dividend Yield: —

Advanced Metrics

Price/Book: 0.26
PEG Ratio: —
Return on Equity: -78.65%
Return on Assets: -54.23%
Gross Margin: 61.90%
Operating Margin: -35264.92%
Profit Margin: 0.00%
Current Ratio: 9.97
Debt/Equity: 0.06
Total Debt: $414.39K
Free Cash Flow: $-3.48M
Revenue Growth: 684.90%
Earnings Growth: —
Enterprise Value: $-4.50M

VRAX Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$8.56K	$156.42K	$6.33K	$12.42K
Cost of Revenue	$9.93K	$105.83K	$59.40K	$4.73K
Gross Profit	-$1.36K	$50.59K	-$53.07K	$7.69K
Research & Development	$2.18M	$1.61M	$2.03M	$3.74M
Selling, General & Admin	$3.55M	$4.57M	$3.99M	$2.67M
Operating Expenses	$5.73M	$6.19M	$6.02M	$6.41M
Operating Income	-$5.73M	-$6.14M	-$6.08M	-$6.40M
EBITDA	-$5.44M	-$6.61M	-$5.80M	-$5.43M
Pretax Income	-$5.46M	-$6.74M	-$6.20M	-$5.93M
Income Tax	$0.00	$0.00	-$136.66K	-$900.24K
Net Income	-$5.46M	-$6.73M	-$6.06M	-$5.02M
Diluted EPS	-128.25	-83.90	-40.62	-12.64
Diluted Shares	42519	80257	149214	397590

VRAX Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$9.35M	$3.59M	$4.23M	$6.44M
Receivables	$0.00	$217.84K	$30.65K	$27.11K
Inventory	$0.00	$60.38K	$94.67K	$0.00
Current Assets	$9.63M	$4.38M	$4.89M	$6.83M
Total Assets	$9.81M	$5.48M	$6.43M	$8.32M
Current Liabilities	$908.40K	$168.85K	$673.21K	$685.02K
Total Debt	$146.25K	$224.30K	$377.00K	$414.39K
Total Liabilities	$908.40K	$345.19K	$964.75K	$989.83K
Retained Earnings	-$11.79M	-$18.53M	-$24.59M	-$29.61M
Shareholders' Equity	$9.13M	$5.37M	$5.70M	$7.58M
Working Capital	$8.73M	$4.21M	$4.22M	$6.14M

VRAX Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$4.18M	-$6.40M	-$4.56M	-$4.62M
Capital Expenditure	-$178.40K	-$1.16M	-$603.89K	-$255.83K
Free Cash Flow	-$4.36M	-$7.56M	-$5.17M	-$4.88M
Depreciation & Amortisation	$0.00	$103.10K	$343.39K	$439.02K
Stock-Based Compensation	$1.73M	$1.01M	$365.31K	$130.41K
Investing Cash Flow	-$178.40K	-$1.16M	-$603.89K	-$255.83K
Financing Cash Flow	$13.69M	$1.80M	$5.81M	$7.09M
Net Change in Cash	$9.33M	-$5.76M	$639.70K	$2.21M

VRAX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q3 2025	Q1 2026
Cash & Equivalents	$4.23M	$3.35M	$6.44M
Receivables	$30.65K	$175.70K	$27.11K
Inventory	$94.67K	$54.19K	$0.00
Current Assets	$4.89M	$4.15M	$6.83M
Total Assets	$6.43M	$5.72M	$8.32M
Current Liabilities	$673.21K	$365.47K	$685.02K
Total Debt	$377.00K	$537.99K	$414.39K
Total Liabilities	$964.75K	$641.52K	$989.83K
Retained Earnings	-$24.59M	-$26.93M	-$29.61M
Shareholders' Equity	$5.70M	$5.31M	$7.58M
Working Capital	$4.22M	$3.78M	$6.14M

Market Snapshot

About

Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection, diagnosis, and risk management of viral diseases. The company develops innovative T-Cell Test technology to assess functional immunity and immunodiagnostic products. Virax aims to advance viral disease diagnostics and prevention strategies globally.